Search the Newsreel

DXC Technology Co. stock underperforms Friday when compared to competitors

DXC Technology Co. (DXC) stock fell 3.66% on Friday, closing at $10.79, while the S&P 500 and Dow Jones Industrial Average also experienced declines. The company's stock is currently trading 31.19% below its 52-week high of $15.68, which was reached on December 17th. This …

DXC Technology (DXC): Glenview Capital and Larry Robbins report 0% beneficial stake

Glenview Capital Management, LLC and Larry Robbins have filed an amended Schedule 13G for DXC Technology (DXC), reporting that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the common stock. This amendment indicates they hold no sole or shared …

Bleichroeder LP Discloses Investment at MDxHealth SA with 33.2% Stake

Bleichroeder LP has disclosed a 33.2% stake in MDxHealth SA after purchasing 24,229,074 shares in a direct offering for $0.454 per share. This investment gives Bleichroeder significant influence and is subject to a 90-day lock-up period. The firm stated its intent for portfolio purposes …

Bleichroeder (MDXH) reports 31.6M-share, 33.2% holding in MDxHealth

Bleichroeder LP and related parties have reported a 33.2% beneficial ownership in MDxHealth SA, totaling 31,648,563 Ordinary Shares. This significant stake was accumulated for investment purposes, including a recent purchase of over 24 million shares in a registered direct offering at $0.454 per share …

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build

Baron group trims CareDx (CDNA) stake to 3.75% in latest 13G/A

Baron Capital Group, including its affiliates BAMCO, Inc. and Baron Capital Management, Inc., and Ronald Baron, have filed an amended Schedule 13G for CareDx, Inc. (CDNA), reporting a beneficial ownership of 1,937,326 shares, which represents 3.75% of the company's common stock. This filing indicates …

MDxHealth SA Stock 12‑Month Price Target Cut to $2.2, Implies 376% Upside

MDxHealth SA's average stock price target has been reduced from $2.8 to $2.2 by analysts, with individual forecasts ranging from $1 to $4. This updated target suggests a potential upside of approximately 376% from its recent closing price. The consensus rating for the stock …

American Century (NYSE: DXC) group discloses 6.4% beneficial stake in DXC

American Century entities have disclosed a significant beneficial ownership in DXC Technology Company, with the American Century group holding a 6.4% stake, comprising 10,436,267 shares as of June 30, 2026. The American Century ETF Trust specifically owns 6.2%, or 10,022,365 shares. These entities, including …

DXC|DXC Technology Co|Price:11.190|Chg%:+0.510

MDxHealth SA (MDXH) (Q2 2026) Earnings Call Highlights: Record Sequential Growth and Strategic De-Risking

MDxHealth SA (MDXH) achieved its largest quarter-over-quarter revenue acceleration in Q2 2026, increasing 14% sequentially, while eliminating a $10.4 million liability. The company strengthened its balance sheet with a $20 million financing and reaffirmed its full-year 2026 revenue guidance of $110 million to $115 …

MDXH Looks 79.0% Undervalued on GF Value™ but Faces Value Trap Warning

MDxHealth SA (MDXH) is currently trading at a significant discount to its GF Value, suggesting a 79.0% undervaluation. However, investors are cautioned due to the company's unprofitability, negative cash flow, and a low GF Score™ of 49/100, indicating financial weakness despite strong growth metrics. …

MDxHealth ADR earnings missed, revenue topped estimates

MDxHealth ADR (NASDAQ: MDXH) reported its second-quarter earnings, missing analyst estimates for EPS but exceeding revenue expectations. The company provided a full-year 2026 revenue guidance that falls within the analyst consensus. Despite topping revenue estimates, MDxHealth ADR's stock has seen significant declines over the …

MDxHealth (NASDAQ: MDXH) lifts Q2 2026 revenue 16% but posts deeper loss

Mdxhealth Sells 44M Shares for $20M Gross as Q2 Net Loss Hits $9.5M

MDxHealth (MDXH) sells 44M shares, lifting total stock to 95.4M

MDxHealth SA completed a Registered Direct Offering, issuing over 44 million ordinary shares at $0.454 per share to institutional investors, raising approximately $20.0 million in net proceeds. These funds will be used for working capital, product development, and expanding commercialization activities. Following this offering, …

Earnings call transcript: MDxHealth tops revenue estimates in Q2 2026

MDxHealth reported Q2 2026 revenue of $27.2 million, exceeding Wall Street estimates of $25.89 million, leading to a 33.12% jump in after-hours trading despite a slight EPS miss. The company saw a 16% year-over-year revenue increase and expects full-year 2026 revenue between $110 million …

DXC Technology Co. stock outperforms competitors on strong trading day

DXC Technology Co. (DXC) shares increased by 4.87% to $11.20, outperforming competitors on a strong trading day for the stock market. This rise ended a two-day losing streak for the company's stock. The S&P 500 Index and Dow Jones Industrial Average also saw gains.

MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates

MDxHealth SA (MDXH) reported a Q2 loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.12 loss. However, the company surpassed revenue estimates with $27.21 million, exceeding the $26.6 million expectation. Despite beating revenue, the stock has significantly underperformed the S&P …

Mdxhealth Reports Second Quarter 2026 Financial Results

Mdxhealth reported a 16% increase in second-quarter 2026 revenue, reaching $27.2 million, driven by strong recovery in its tissue-based business and integration of ExoDx. The company reaffirmed its 2026 revenue guidance of $110-115 million and expects to return to positive adjusted EBITDA by the …

DXP Enterprises (DXPE) Q2 2026 Earnings Call Transcript

DXC Technology (DXC) sees Millennium group report 4.1% ownership stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective beneficial ownership of 6,613,586 shares of DXC Technology (DXC) common stock, representing 4.1% of the outstanding shares. This information comes from an amended Schedule 13G filing, indicating that the …

DXC Technology Co. stock underperforms Wednesday when compared to competitors

DXC Technology Co. (DXC) shares fell by 1.20% to $10.68 on Wednesday, marking its second consecutive day of losses. This underperformance occurred during a mixed trading session where the S&P 500 Index rose 0.26% and the Dow Jones Industrial Average slightly declined by 0.04%.

Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?

CareDx (CDNA) reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue guidance to US$490–500 million, while also completing a share buyback and filing for an ESOP-related share registration. Despite this positive financial performance and a Medicare LCD confirming coverage …

CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares

CareDx, Inc. insider Peter Maag has filed a notice to sell 7,000 shares of common stock, valued at $328,237.70, through Morgan Stanley Smith Barney LLC. These shares originated from restricted stock awards in late 2023 and early 2024. The filing also disclosed recent sales …

Q2 Earnings Outperformers: DXP (NASDAQ:DXPE) And The Rest Of The Maintenance and Repair Distributors Stocks

Baron Discovery Fund Gains from Strategic Accumulation of CareDx (CDNA)

The Baron Discovery Fund increased its position in CareDx (CDNA) after shares declined in Q3 2025 due to a draft local coverage decision by CMS that threatened reimbursement for its diagnostic tests. The fund believed the stock was undervalued at $11-12, representing a worst-case …

DXP Enterprises, Inc. $DXPE Stock Position Reduced by Wasatch Advisors LP

Wasatch Advisors LP has reduced its stake in DXP Enterprises, Inc. (NASDAQ:DXPE) by 29.7% in the second quarter, now owning 445,575 shares valued at $75,186,000. Other institutional investors have also adjusted their positions, while company insiders, including Director Timothy P. Halter and CMO Paz …

DXC Technology Company. (NYSE:DXC) Given Consensus Rating of "Reduce" by Analysts

Analysts have issued a consensus "Reduce" rating for DXC Technology (NYSE:DXC), with three analysts recommending selling and seven recommending holding, and an average 12-month price target of $12.44. The company reported quarterly EPS of $0.40, slightly below estimates, but revenue of $3.0 billion exceeded …

MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal

MiMedx Group has clarified the termination fees for its merger with Sanara MedTech Inc., stating Sanara would owe $9.66 million in specific cases and MiMedx $22.54 million if it fails to close. The deal offers Sanara shareholders $33.00 cash plus 0.4735 shares of MiMedx …

Why DXP Enterprises (DXPE) Is Up 18.1% After Pumping and Water Platform-Fueled Q2 Earnings

DXP Enterprises (DXPE) saw an 18.1% stock increase after reporting strong Q2 2026 earnings, driven by growth in its Innovative Pumping Solutions and Water platforms, supported by recent acquisitions. While the company's financial results show increased sales and net income, its strategy of growth …

Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees

Sanara MedTech Inc. has confirmed the terms of its merger with MiMedx Group, Inc., where each Sanara share will convert into $33.00 in cash and 0.4735 shares of MiMedx common stock, valued at $2.00 per share. This amendment also corrects previously misstated termination fees, …

GeneDx Holdings (WGS) Is Up 14.8% After Loss-Making Q2, New Capital Raise And Guidance Reaffirmation

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md., August 11, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of …